Mayne Pharma Group Ltd. · ASX:MYX

Mayne Pharma — Rodman & Renshaw Annual Investment Conference 2015

11 slides from Mayne Pharma's conference presentation, Sep 9, 2015

  1. Slide 1: Mayne Pharma Group Limited Company Presentation

    Mayne Pharma Group Limited Company Presentation Rodman & Renshaw Annual Investment Conference September 9th, 2015 Stefan Cross, President, Mayne Pharma USA

  2. Slide 2: Mayne Pharma is a diverse global pharma company

    Mayne Pharma is a diverse global pharma company By geography ● Mayne Pharma is an Australian-listed specialty pharmaceutical company, headquartered in Adelaide 5% USA 17% ● Develops and manufactures generic and proprietary Australia A$141m pharmaceuticals which are distributed globally either Rest o

  3. Slide 3: Company history

    Company history 1845 Leading Australian healthcare company with over 150 years of history 1970s  Development of enteric coated erythromycin (Eryc™)  FDA approval and first US sales of Eryc™ by Warner Lambert (Warner Chilcott) FH Faulding & Co 1980s  Salisbury site acquired in 1983  Development o

  4. Slide 4: Mayne Pharma's international footprint

    Mayne Pharma’s international footprint Commercial office Raleigh, North Carolina Product development and manufacturing facility space. FDA approved. US$6514.6 hectare facility at Greenville, North Carolina has 99,200ft2 of manufacturing m strategic investment in new greenfield oral dose commercial m

  5. Slide 5: Mayne Pharma's business structure

    Mayne Pharma’s business structure United States Rest of world US Generic Products Metrics US Specialty Brands Mayne Pharma (GPD) Contract Services (SBD) International (MPI) (MCS)  Develops, manufactures,  Responsible for the  Provides contract  Develops, manufactures, Overview markets and distri

  6. Slide 6: FY15 operational and financial highlights

    FY15 operational and financial highlights ● Transformational US$50m Doryx™ acquisition completed which has diversified and transformed the earnings profile ● US Specialty Brands Division created with a 60+ person sales team to market specialty brands in the US ● Expanded marketed product portfolio a

  7. Slide 7: Doryx - the "game changer" for Mayne Pharma

    Doryx™ - the “game changer” for Mayne Pharma 1 Transformed earnings base following Doryx acquisition 2 Attractive market fundamentals in US dermatology space 3 Optimize Doryx sales through: ● Mayne Pharma’s sales force, which will be focused and dedicated to marketing Doryx ● Further product pricing

  8. Slide 8: Development pipeline expected to drive long-term sustainable growth

    Development pipeline expected to drive long-term sustainable growth ● Team of 60+ professionals in R&D with particular US Pipeline statistics – IMS market size (US$bn)1 August 2015 expertise in formulating complex oral dose forms including - highly potent compounds 8.0 - schedule II-V controlled sub

  9. Slide 9: 5 pillars of our corporate strategy

    5 pillars of our corporate strategy 1. US retail generics 4. Strategic acquisitions, 3. R&D maximization maximization licensing and partnerships 2. Establish a US branded 5. Optimize and grow US specialty franchise contract services 9

  10. Slide 10: Outlook

    Outlook US Specialty ● New segment will capture full year contribution from Doryx Brands Division ● Recent launch of 50mg Doryx tablet is expected to grow the franchise (SBD) ● Expected monthly EBITDA contribution of US$2.7m on average in FY16 from US Doryx franchise US Generic ● US generic market g

  11. Slide 11: A specialty pharmaceutical company with an increasingly diversified portfolio

    A specialty pharmaceutical company with an increasingly diversified portfolio of products, technologies and footprint 11

Mayne Pharma Group — Rodman & Renshaw Annual Investment Conference 2015 on 6ix